Blockchain Registration Transaction Record

Oragenics Partners with Receptor.AI to Accelerate Neurological Drug Development

Oragenics partners with Receptor.AI using AI technology to accelerate neurological drug development. Collaboration focuses on optimizing compounds for brain conditions through intranasal delivery.

Oragenics Partners with Receptor.AI to Accelerate Neurological Drug Development

This collaboration represents a significant advancement in neurological drug development that could transform treatment options for millions of patients suffering from brain-related conditions. The integration of artificial intelligence with Oragenics' proprietary intranasal delivery technology has the potential to dramatically accelerate the discovery and optimization of new therapies for conditions ranging from concussion to neurodegenerative diseases. For patients, this could mean faster access to more effective, targeted treatments that bypass traditional delivery limitations. The partnership also demonstrates how AI is revolutionizing pharmaceutical development, potentially reducing both time and costs associated with bringing new drugs to market. Given the growing global burden of neurological disorders and the limited treatment options currently available, this innovative approach could have far-reaching implications for healthcare systems and patient outcomes worldwide.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xe47111c1b35729479b306cf79ce8248f64ee852dc38fc94167e94a156429487f
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintpear0C4I-89c2c66972e83127ddacb2eaafdfb640